Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS 4: Oral semaglutide 25 mg for overweight or obesity
2021-006534-40Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Oral semaglutide 25 mg once daily with Placebo once daily (2 arms). Primary endpoints: Relative change in body weight from baseline to week 64 and Change in physical function from baseline to week 64. Started Aug 2022; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2021-006534-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006534-40.